General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded without agreement
Manufacturer:
AVIR Pharma Inc.
Indication:
Eosinophilic Esophagitis (Maintenance)
Last updated July 20, 2022
Status:
Concluded without agreement
Manufacturer:
AVIR Pharma Inc.
Indication:
Eosinophilic Esophagitis (Induction)
Last updated July 20, 2022
Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
Status:
Concluded with an LOI
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Indication:
Cystic Fibrosis, F508del CFTR mutation in patients aged 6 years and older
Last updated July 7, 2022
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Metastatic colorectal cancer (mCRC) in patients with a BRAF V600E mutation, as detected by a validated test, after prior therapy (in combination with cetuximab)
Last updated July 6, 2022
Braftovi/Mektovi (encorfenib/binimetinib)
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test, (encorafenib and binimetinib in combination)
Last updated July 6, 2022
Status:
Concluded without agreement
Manufacturer:
Sanofi Genzyme Canada
Indication:
Asthma
Last updated June 28, 2022
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Neuromyelitis optica spectrum disorder (NMOSD)
Last updated June 28, 2022
Breztri Aerosphere (budesonide/glycopyrronium/ formeterol fumarate dihydrate)
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Chronic Obstructive Pulmonary Disease (COPD)
Last updated June 15, 2022
Status:
Concluded with an LOI
Manufacturer:
Celgene Inc.
Indication:
Acute myeloid leukemia (AML), Maintenance therapy in adult patients who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation (HSCT)
Last updated June 7, 2022
Status:
Concluded without agreement
Manufacturer:
BGP Pharma ULC, d.b.a. Viatris Canada
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated June 1, 2022